Genedata said this week that MorphoSys has licensed Genedata Biologics, its research and development data management platform, to support efforts to develop therapeutic antibodies.
MorphoSys will use the platform to support internal and partner-based biologics discovery efforts for lead finding and optimization, Genedata said.
Genedata Biologics integrates with the MorphoSys laboratory infrastructure and interacts with proprietary discovery technologies, including the MorphoSys HUCAL antibody library, screening, and expression platforms.
Markus Enzelberger, MorphoSys’ vice president and head of discovery alliances and technologies, said in a statement that Genedata’s platform provides “comprehensive biologics data management functionality and the flexibility needed to support our proprietary antibody discovery processes and technology portfolio.”
Earlier this year, biopharmaceutical firm UCB implemented a biological registration system for protein-based lead candidates, dubbed BioQuest, that’s based on the Genedata Biologics software (BI 3/25/2011).
In July, the Integrated Phenotype-Genotype project — a consortium of companies in the biotechnology industry — tapped Genedata’s Selector software to analyze and manage data from production strains and processes in industrial biotechnology. Furthermore, Takeda Pharmaceutical expanded its license for Genedata Expressionist this year as well (BI 7/29/2011).
Othmar Pfannes, Genedata’s CEO, described MorphoSys' choice to use Genedata Biologics as “another major milestone” for the company’s “growing biopharma business.”
He added that Genedata plans to “continue to invest in the advancement of protein therapeutics, and support those engaged in the field.”